" class="no-js "lang="en-US"> Dan Mendelson - Medtech Alert
Saturday, June 10, 2023

Breaking News

Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430 FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Sir Richard Roberts Elected to National Academy of Sciences Rocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy (ACM) Azafaros Announces Enrollment of First Patient in Phase 2 RAINBOW Study Evaluating AZ-3102 in GM2 and NP-C Patients Kate Therapeutics Debuts With $51 Million Series A to Develop Next-Generation Genetic Medicines to Treat Muscle and Heart Diseases
Dan Mendelson | Pharmtech Focus

Dan Mendelson

About Dan Mendelson

CEO of Morgan Health | Focused on innovation in employer-sponsored healthcare

Related Story

Appointments

 Dr. Cheryl Pegus

Dr. Cheryl Pegus, Former Walmart EVP of Health & Wellness, Joins Morgan Health

November 21 2022

Dr. Cheryl Pegus, a nationally-recognized leader for her work to deliver affordable, high-quality care to millions of […]